Neurotoxicity Induced by Bupivacaine via T-Type Calcium Channels in SH-SY5Y Cells

Xianjie Wen¹,²*, Shiyuan Xu¹*, Hongzhen Liu², Qinguo Zhang¹*, Hua Liang², Chenxiang Yang², Hanbing Wang²

¹ Department of Anesthesiology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China; ² Department of Anesthesiology, The First People’s Hospital of Foshan & Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong Province, China

Abstract

There is concern regarding neurotoxicity induced by the use of local anesthetics. A previous study showed that an overload of intracellular calcium is involved in the neurotoxic effect of some anesthetics. T-type calcium channels, which lower the threshold of action potentials, can regulate the influx of calcium ions. We hypothesized that T-type calcium channels are involved in bupivacaine-induced neurotoxicity. In this study, we first investigated the effects of different concentrations of bupivacaine on SH-SY5Y cell viability, and established a cell injury model with 1 mM bupivacaine. The cell viability of SH-SY5Y cells was measured following treatment with 1 mM bupivacaine and/or different dosages (10, 50, or 100 μM) of NNC 55-0396 dihydrochloride, an antagonist of T-type calcium channels for 24 h. In addition, we monitored the release of lactate dehydrogenase, cytosolic Ca²⁺ ([Ca²⁺]ᵱ) cell apoptosis and caspase-3 expression. SH-SY5Y cells pretreated with different dosages (10, 50, or 100 μM) of NNC 55-0396 dihydrochloride improved cell viability, reduced lactate dehydrogenase release, inhibited apoptosis, and reduced caspase-3 expression following bupivacaine exposure. However, the protective effect of NNC 55-0396 dihydrochloride plateaued. Overall, our results suggest that T-type calcium channels may be involved in bupivacaine neurotoxicity. However, identification of the specific subtype of T calcium channels involved requires further investigation.

Introduction

Regional anesthetics have been used widely in clinical settings and as postoperative analgesics, because of their reduced systemic effects [1,2]. However, local anesthetics may cause neurotoxicity, such as transient neurological syndrome (TNS), and cauda equina syndrome, which has raised concerns about their use [3,4]. One multicenter study found that the incidence of TNS was approximately 8.1%, which resulted in pain or sensory abnormalities in the lower back, buttocks, or lower extremities, with symptoms beginning after spinal anesthesia and lasting for hours to 4 days [5]. Although there is low incidence of anesthetic-induced cauda equina syndrome, it results in severe damage to neurons [6–8].

Local anesthetics can cause cell apoptosis, induce the release of reactive oxygen species and lactate dehydrogenase (LDH) [9,10]. Several studies have shown that lidocaine, bupivacaine, tetracaine, dibucaine, and procaine can induce apoptosis [11]. The underlying mechanisms of local anesthetic neurotoxicity are not clearly understood. Previous studies indicated that intracellular calcium overload is involved in local anesthetic-induced neurotoxicity [12,13]. Extracellular calcium influx and intracellular calcium store release are the most important factors for local anesthetic-induced calcium overload. Also, an influx of extracellular calcium can induce calcium-dependent release of intracellular calcium stores [14,15].

The main route of extracellular calcium influx into cells is via voltage-dependent calcium channels (VDCCs) [16]. Currents arising from VDCCs are subdivided into two major classes based on the membrane potential at which they become activated: high-voltage activated (HVA), which are further divided into L-, P-, Q-, N- and R-subtypes, and low-voltage activated (LVA) or transient (T-type) Ca²⁺ currents, which are further divided into Cav3.1, Cav3.2 and Cav3.3 [17]. The T subtype of VDCCs are known to perform several roles in neurons, such as lowering the threshold for action potentials, promoting burst firing, oscillatory behavior, and enhancing synaptic excitation [17]. With electrophysiological characteristics, such as activation at resting potential, T-type calcium channels act as pacemakers in many pathological and physiological conditions [18,19]. This pacemaker-like activity of T-type calcium channels allows them to regulate the excitability of neurons. T-type calcium channels can be activated at the resting potential, and then extracellular calcium ions enter into the cells by T-type calcium channels. On the one hand, cell membrane depolarization induced by T-type currents activates the HVA channels and promotes extracellular calcium ion entry into the cell. On the other hand, T-type currents prime calcium-induced calcium release (CICR) [20].

* E-mail: xjwen166@163.com (XW); xushiyuan335@sina.com.cn (SX); 13127132638@qq.com (QZ)
Although calcium channel blockers (CCB) can cause cancer cell growth, they can inhibit the neuronal apoptosis in several neuron injury models [21–23]. For example, the L-type voltage-gated calcium channel blocker, nifedipine, lowered the intracellular Ca^{2+} concentration of the cerebellar granule cells treated with kainate from 1543 nM to 764 nM and reduced kainate neurotoxicity. Yagami and colleagues found that S-312-d, another L-type voltage sensitive calcium channel blocker, rescued cortical neurons from apoptosis induced by beta amyloid and human group II A secretory phospholipase A2. The neuroprotective effects of CCB were shown by lowering the intracellular Ca^{2+} concentration. We conjectured that T-type calcium channels, with the pacemaker-like activity, may be involved with the calcium overload of local anesthetic-induced neurotoxicity. In this study, we hypothesize that neurotoxicity induced by bupivacaine involves T-type calcium channels. Therefore, we employed an in vitro model of cytotoxicity using SH-SY5Y cells treated with bupivacaine. In addition, we monitored the effect of NNC 55-0396 dihydrochloride, a highly selective T-type calcium channel blocker that does not significantly alter currents mediated by other subtypes of calcium channels [24], on cell viability, LDH release, cytosolic Ca^{2+} ([Ca^{2+}]_{i}), apoptosis, and caspase-3 expression, following bupivacaine treatment.

### Materials and Methods

#### Materials

The SH-SY5Y cell line was purchased from Shanghai Institutes for Biological Sciences (Shanghai, China). Goat polyclonal anti-caspase-3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), bupivacaine hydrochloride and NNC 55-0396 dihydrochloride were purchased from Sigma (St. Louis, MO, USA) and Boston Biochem (Boston, MA, USA), respectively. Other reagents used in this study were as follows: DMEM/F12 medium and fetal bovine serum ( Gibco, Grand Island, NY, USA), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-tetrazolium bromide (MTT; Beyotime, Nantong, China), Quest Fluo-8 AM ester (AAT Bioquest Inc., Sunnyvale, CA, USA), Hoechst 33258 (Beyotime), annexin V-FITC and propidium iodide (KeyGEN, Nanjing, China), and the LDH cytotoxicity detection kit (Beyotime). All other reagents were from commercial suppliers and of standard biochemical quality.

#### Cell Culture

SH-SY5Y cells were cultured in DMEM/F12 medium with 15% (v/v) fetal bovine serum, 100 units/mL of penicillin and 100 μg/mL of streptomycin, and maintained in a humidified 5% CO_2 incubator at 37°C. The medium was replaced every 2 days.

#### Viability of the Cell Treated with Different Concentration Bupivacaine

To investigate the effects of different bupivacaine concentrations on SH-SY5Y cell viability, we treated SH-SY5Y cells with 0.1, 0.5, 0.75, 1, 2, 5, or 10 mM bupivacaine for 24 h. The effects of the...
different bupivacaine concentrations on SH-SY5Y cell viability were evaluated by the MTT assay.

**Experimental Classification**

Bupivacaine hydrochloride in powder form was dissolved in medium with serum resulting in the final concentration of bupivacaine being 1 mM, based on the results from the cell viability experiment. Cells were pretreated with 10, 50, or 100 μM NNC 55-0396 dihydrochloride (NNC) 30 min prior to treatment with either the culture medium containing 1 mM bupivacaine or an equivalent amount of medium alone for 6, 12, or 24 h. The experimental groups were: (1) NNC 55-0396 dihydrochloride 100 μM (S+NNC 100 group), (2) bupivacaine (S+B group), (3) bupivacaine+NNC 10 μM (S+B+NNC 10 group), (4) bupivacaine+NNC 50 μM (S+B+NNC 50 group), (5) bupivacaine+NNC 100 μM (S+B+NNC 100 group), and (6) non-pretreated (S group).

**MTT Assay**

Cell viability was measured using the MTT assay as previously described [25]. The cells were seeded into 96-well plates at a concentration of 5×10^3 cells/well with 100 μL culture medium per well. The cells were exposed to either 1 mM bupivacaine or an equivalent amount of medium for 6, 12, or 24 h. MTT (20 μL) was added to each well and incubated at 37°C for 4 h. The optical density of the homogenous purple solution was measured using a spectrophotometer (Bio-Tek, Winooski, VT, USA). The control group without bupivacaine treatment was set as 100% cell survival and all other groups were normalized to the corresponding control values.

Figure 4. Bupivacaine treatment leads to an increase in cytosolic Ca^{2+} ([Ca^{2+}]_i). SH-SY5Y cells were either pretreated with the indicated concentrations of NNC 55-0396 dihydrochloride or left untreated prior to 1 mM bupivacaine treatment for 24 h. [Ca^{2+}]_i levels were measured by Quest Flu-8 AM ester (mean±SD, n = 6)). A: Representative image of Quest Flu-8 AM ester flow cytometry analysis. B: [Ca^{2+}]_i levels in the different treatment groups. aP<0.05 vs. S group; bP<0.05 vs. S+NNC 100 group; cP<0.05 vs. S+B group; dP<0.05 vs. S+B+NNC 10 group.

doi:10.1371/journal.pone.0062942.g004
LDH Assay
LDH activity was determined using an LDH cytotoxicity detection kit after cells were exposed to 1 mM bupivacaine, or an equivalent amount of medium for 6, 12, or 24 h [26]. The incubation solution was collected from the 12-well plates at the end of each experiment, and then centrifuged at 13,000 × g for 10 min. The supernatant (100 μL) was transferred to 96-well plates and incubated with the same amount of reaction mixture. LDH activity was determined using a colorimetric assay at an absorbance wavelength of 492 nm and a reference wavelength of 655 nm using a spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA). Background absorbance from the cell-free buffer solution was subtracted from all absorbance measurements. After removal of the buffer from 12-well plates, 1% (v/v) Triton X-100 solution was applied to the remaining cells. The percentage of LDH released into the incubation buffer was calculated as follows: spontaneously released LDH into the buffer/spontaneously released LDH into the buffer + intracellular LDH released by Triton X-100.

Measurements of Cytosolic Ca²⁺
Cytosolic Ca²⁺ ([Ca²⁺]i) from each group after treatment, with or without drugs for 24 h, was measured with Quest Fluo-8 AM ester. Briefly, a 5 mM stock solution of Quest Fluo-8 AM ester was prepared in high-quality anhydrous DMISO and a 10 mM working solution was prepared in Hanks and HEPES buffer (HHBS). The Quest Fluo-8 AM ester reagent concentration was 5 μM. The cells were incubated with the Quest Fluo-8 AM ester for 20 min at room temperature. Cells were washed twice in HHBS to remove excess probe. The experiments were analyzed at excitation and emission wavelengths of 490 and 525 nm, respectively. To determine the free calcium concentration in the solution ([Ca²⁺]i) or the Ki of a single-wavelength calcium indicator, the following equation was used: [Ca²⁺]i = Ki(F - Fmin)/Fmax - F. Where F is the fluorescence of the indicator at experimental calcium levels, Fmin is the fluorescence in the absence of calcium and Fmax is the fluorescence of the calcium-saturated probe. The dissociation constant (Ki) is a measure of the affinity of the probe for calcium, which is provided in the kit manual.

Detection of Apoptosis by Flow Cytometry
After cells were treated as described above for 24 h, the cells were seeded into 24-well plates at a concentration of 5 × 10⁵ cells/well, with 500 μL culture medium per well. Cells were rinsed with phosphate buffered saline (PBS) and collected. Each pellet was resuspended in 500 μL binding buffer. In addition, 5 μL annexin V-FITC and 5 μL propidium iodide were added to each well. After a 5 min incubation, apoptotic cell death was measured by flow cytometry.

Apoptotic Cell Death Detected with Hoechst 33258
Cells in 24-well plates were rinsed 3 times with PBS and stained with Hoechst 33258. Subsequently, the cells were examined and photographed under a fluorescence microscope (Nikon ECLIPSE TE2000-u, Tokyo, Japan) with a UV excitation wavelength of 300–500 nm. Apoptotic cells were defined on the basis of nuclear morphology changes: chromatin condensation and fragmentation. The number of apoptotic and normal cells was counted manually by researchers blinded to the treatment schedule. For each well, at least 5 different fields were examined and the apoptosis rate was expressed as the percentage of apoptotic cells to the total number of cells counted.

Detection of Caspase-3 Protein Expression by Western Blotting
Culture flasks or plates were quickly rinsed with chilled PBS. Cells were collected using a plastic cell scraper, removed, and lysed in lysis buffer A (20.0 mMol/L Tris-HCl, 1.0 mMol/L Na3VO4, 1.5 mMol/L MgCl2, 10.0 mMol/L KCl, 0.1 mMol/L ethylene-diaminetetraacetic acid (EDTA), 0.1 mMol/L ethylene glycol tetraacetic acid (EGTA), 0.5 mMol/L phenylmethylsulfonyl fluoride (PMSF), and 0.02% (w/v) protease inhibitor cocktail (pH 7.9)). After addition of 90 μL NP-40 (10% (v/v)), samples were shaken for 30 sec and then centrifuged at 800 × g for 15 min at 4°C. The supernatants were centrifuged at 10,000 × g for 1 h at 4°C. The samples were then homogenized in lysis buffer B (20.0 mMol/L Tris-HCl, 0.03 mMol/L Na2VO4, 2.0 mMol/L MgCl2, 10.0 mMol/L KCl, 2.0 mMol/L EDTA, 2.0 mMol/L EGTA, 2.0 mMol/L PMSF, 0.1% (v/v) Triton X-100, 5.0 mMol/L NaF, and 0.02% (w/v) protease inhibitor cocktail). The samples were centrifuged at 10,000 × g for 1 h at 4°C, and the supernatants were used for western blot analysis. Protein concentration was determined using the Bradford method, and protein samples were stored at −80°C. Protein samples were dissolved in 4 × sample buffer (250 mMol/L Tris-HCl, 200 mMol/L sucrose, 300 mMol/L dithiothreitol, 0.01% (w/v) Coomassie brilliant blue-G, and 8% (w/v) SDS, pH 6.8), and were subsequently denatured at 95°C for 5 min. Equivalent amounts of protein were separated on a 7.5% (w/v) sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and transferred onto nitrocellulose membranes. The membranes were incubated overnight at 4°C with either goat polyclonal anti-caspase-3 antibody or anti-β-actin (1:500; Santa Cruz Biotechnology, Santa Cruz CA, USA). The membranes were washed extensively with Tris-buffered saline/Tween-20 and incubated for 2 h in peroxidase-conjugated rabbit anti-goat IgG secondary antibody (1:500; Santa Cruz Biotechnology) at room temperature. The immune complexes were detected by enhanced chemiluminescence, and membranes were then exposed to X-ray film. Quantification of protein bands was conducted by scanning the films and importing the images into Adobe Photoshop software (Adobe, San Jose, California, USA). Scanning densitometry was used for semi-quantitative analysis of the data. Caspase-3 protein was normalized to β-actin levels.

Statistical Analysis
Results are presented as the mean ± SD. Factorial design ANOVA (SPSS 11.0 statistical software, IBM, USA) was used to analyze the data from the MTT assay, LDH assay, apoptosis assay and western blot assay. Multiple comparisons tests were performed by LSD. A probability value of P < 0.05 was considered to be statistically significant.

Results
Cell Viability
Viability of SH-SY5Y cells dose-dependently decreased with increasing concentrations of bupivacaine. Treatment with 0.1, 0.5, 0.75, 1, 2, 5, and 10 mM bupivacaine for 24 h resulted in 58 ± 6%, 39 ± 5%, 27 ± 4%, 15 ± 3%, 5 ± 2%, and 2 ± 1% viability, respectively (Fig. 1).

Compared with the S group, cell viability of SH-SY5Y cells in the S+NNC 100 group was not significantly different at 6, 12, and 24 h. However, 1 mM bupivacaine caused marked cell injury, and cell viability in the S+B group was 47 ± 7%, 36 ± 5% and 26 ± 5% at 6, 12, and 24 h, respectively. Compared with the S+B group, NNC 55-0396 dihydrochloride pretreatment with the three different concentrations protected SH-SY5Y cells against bupiva-
caine-induced cell injury at 6, 12, and 24 h. Viability of SH-SY5Y cells treated with NNC 55-0396 dihydrochloride improved to 60±6%, 48±6% and 35±4% in the S+B+NNC 10 group, 70±7%, 61±7%, and 45±4% in the S+B+NNC 50 group, and 67±7%, 62±7% and 46±4% in the S+B+NNC 100 group, respectively. Although there was a significant difference between SH-SY5Y cells in the S+B+NNC 10 group and the S+B+NNC 50 and S+B+NNC 100 groups, there were no significant differences between SH-SY5Y cells in the S+B+NNC 50 and S+B+NNC 100 groups (Fig. 2).

LDH Activity

SH-SY5Y cells in the S group showed marked LDH release, with extracellular LDH being 8.8±1.9%, 9.2±1.6%, and 10.1±1.2% of total LDH at 6, 12, and 24 h, respectively. In addition, there was no significant change in LDH release in SH-SY5Y cells pretreated with 100 μM NNC 55-0396 dihydrochloride for 6, 12, and 24 h. However, incubation with 1 mM bupivacaine increased extracellular LDH release to 20.7±2.1%, 27.1±2.8% and 31.3±2.9% at 6, 12, and 24 h, respectively. Interestingly, SH-SY5Y cells pretreated with NNC 55-0396 dihydrochloride resulted in a reduction in LDH release following bupivacaine treatment. Extracellular LDH at 6, 12, and 24 h was 17.3±1.6%, 22.2±2.7% and 25.3±1.6%, respectively, in the S+B+NNC 10 group; was 14.3±1.8%, 16.7±1.6% and 20.1±1.7% in the S+B+NNC 50 group; and was 13.5±1.9%, 16.5±2.1% and 20.8±1.9% in the S+B+NNC 10 group. Although there was a significant difference between SH-SY5Y

Figure 5. NNC 55-0396 dihydrochloride protects SH-SY5Y cells from bupivacaine-induced apoptosis. Cells were either treated with the indicated concentrations of NNC 55-0396 dihydrochloride or left untreated prior to 1 mM bupivacaine treatment for 24 h. Apoptosis was measured by Annexin-V staining with flow cytometry (% mean±SD, n=6). A: Representative image from the flow cytometric analysis. B: Rates of apoptosis in the different treatment groups. aP<0.05 vs. S group; bP<0.05 vs. S+B+NNC 100 group; cP<0.05 vs. S+B group; dP<0.05 vs. S+B+NNC 10 group.

doi:10.1371/journal.pone.0062942.g005
cells in the S+B+NNC 10 group and the S+B+NNC 50 and S+B+NNC 100 groups, there were no significant differences between SH-SY5Y cells in the S+B+NNC 50 and S+B+NNC 100 groups (Fig. 3).

Changes in Cytosolic Ca$$^{2+}$$

$$[\text{Ca}^{2+}]_i$$ in SH-SY5Y cells in the S group and S+B+NNC 100 group was $358 \pm 25$ nM and $372 \pm 32$ nM, respectively. However, $$[\text{Ca}^{2+}]_i$$ in the S+B group increased dramatically after treatment with 1 mM bupivacaine for 24 h to $715 \pm 35$ nM. SH-SY5Y cells pretreated with NNC 55-0396 dihydrochloride resulted in a reduction of $$[\text{Ca}^{2+}]_i$$ following bupivacaine exposure. $$[\text{Ca}^{2+}]_i$$ of the cells in the S+B+NNC 10, S+B+NNC 50 and S+B+NNC 100 groups was $657 \pm 29$ nM, $619 \pm 37$ nM and $585 \pm 39$ nM, respectively (See Fig. 4).

Apoptotic Cell Death Measured by Flow Cytometry

The rate of apoptosis in SH-SY5Y cells from the S and S+B+NNC 100 group was 12.5$\pm$2.7% and 12.9$\pm$2.3% respectively. After treatment with 1 mM bupivacaine for 24 h, the rate of apoptosis in the S+B group dramatically increased to 41.6$\pm$3.0%. NNC 55-0396 dihydrochloride pretreatment reduced the amount of apoptotic cell death following bupivacaine exposure, and the rates of apoptosis in the S+B+NNC 10, S+B+NNC 50 and S+B+NNC 100 groups were 36.2$\pm$2.2%, 28.7$\pm$3.2% and 25.1$\pm$2.8%, respectively. Although there was a significant difference between SH-SY5Y cells in the S+B+NNC 10 group and the S+B+NNC 50 and S+B+NNC 100 groups, there were no significant differences between SH-SY5Y cells in the S+B+NNC 50 and S+B+NNC 100 groups (Fig. 5).

Detection of Apoptosis Using Hoechst 33258

Nuclear alterations of apoptotic cells were observed using Hoechst 33258 nuclear staining. As seen in Figure 6, apoptotic

---

**Table 1. Apoptosis measured by Hoechst 33258 staining (%)**, mean$\pm$S.D, n = 6.

| Group          | Apoptosis |
|----------------|-----------|
| S              | 7.5$\pm$1.9 |
| S+NNC 100      | 7.5$\pm$2.3 |
| S+B            | 49.2$\pm$1.0$^{ab}$ |
| S+B+NNC 10     | 36.3$\pm$2.2$^{abc}$ |
| S+B+NNC 50     | 25.5$\pm$2.7$^{ab}$ |
| S+B+NNC 100    | 24.5$\pm$2.9$^{ab}$ |

$^a$P<0.05 vs. S group;  
$^b$P<0.05 vs. S+NNC 100 group;  
$^c$P<0.05 vs. S+B group;  
$^d$P<0.05 vs. S+B+NNC 10 group.

doi:10.1371/journal.pone.0062942.t001

Figure 6. NNC 55-0396 dihydrochloride protects SH-SY5Y cells from bupivacaine-induced nuclear alterations during apoptosis. Cells were either treated with the indicated concentrations of NNC 55-0396 dihydrochloride or left untreated prior to 1 mM bupivacaine treatment for 24 h. Nuclear morphology was evaluated by Hoechst 33258 staining (>200). Apoptotic cells were observed to have condensed or segmented nuclei accompanied by bright blue fluorescence.

doi:10.1371/journal.pone.0062942.g006
cells were observed to have condensed or segmented nuclei accompanied by bright blue fluorescence. Data analysis revealed similar results to that of flow cytometry (Table 1).

**Detection of Caspase-3 Expression by Western Blotting**

The expression of cleaved caspase-3 (active form) and procaspase-3 (inactive form) were measured. The expression of procaspase-3 in SH-SY5Y cells in the S group and S+NNC 100 group was markedly higher than in the other groups. After treatment with 1 mM bupivacaine for 24 h, the expression of procaspase-3 in SH-SY5Y cells decreased and the expression of caspase-3 dramatically increased. However, NNC 55-0396 dihydrochloride pretreatment prevented the bupivacaine-induced reduction in procaspase-3. Therefore, NNC 55-0396 dihydrochloride pretreatment inhibited caspase-3 cleavage. Although the effects of NNC 55-0396 dihydrochloride were significantly different between SH-SY5Y cells in the S+NNC 50 and S+NNC 100 groups, there were no significant differences between SH-SY5Y cells in the S+NNC 50 and S+NNC 100 groups (Fig. 7).

**Discussion**

Generally, nerve damage resulting from local anesthetic exposure is related to the dose, concentration, and the time of exposure to the local anesthetic [27]. The precise mechanism of local anesthetic-induced nerve damage remains unclear. An intracellular overload of calcium may be a contributing factor to local anesthetic-induced nerve injury [12,13]. Calcium is an important mineral essential for cellular function. Calcium can serve as a chemical signal in cells, and its levels are carefully regulated. One intriguing role of calcium is its ability to trigger apoptosis, a controlled form of cell death. Extracellular calcium ions can enter cells through voltage-dependent calcium channels or ligand-gated calcium channels, and activate calcium-dependent enzymes. Over-activation of these enzymes can cause nerve damage. At the same time, calcium ions entering cells can produce calcium-induced calcium release (CICR), causing an overload of intracellular calcium, and subsequently apoptosis and nerve damage [14].

In the present study, we detected the intracellular Ca\(^{2+}\) concentration with Fluo-8, with absorption and emission peaks at 490 nm and 514 nm, respectively. They can be excited with an argon ion laser at 488 nm, and their emitted fluorescence increases with increasing concentrations of Ca\(^{2+}\). Compared with Fluo-3 or Fluo-4, Fluo-8 is an excellent probe to use with high sensitivity. In this study, we found intracellular Ca\(^{2+}\) concentrations of SH-SY5Y cells treated with 1 mM bupivacaine for 24 h increased sharply and NNC, inhibited the rise of the intracellular Ca\(^{2+}\) concentration and prevented the apoptosis induced by bupivacaine.

The Cav3 family T-type calcium channels generate low-voltage-activated Ca\(^{2+}\) currents, and play an important role in many physiological and pathological processes, such as the regulation of cellular excitability, neurotransmitter secretion and release, motor coordination and function, learning and memory, epilepsy, and neuropathic pain [18,28]. In our previous study, we monitored the protein and mRNA expression of T-type calcium channels in SH-SY5Y cells [29]. In this study, we found that 1 mM bupivacaine induced apoptosis in SH-SY5Y cells, activated caspase-3, and increased LDH release. However, NNC 55-0396 dihydrochloride, an antagonist of T-type calcium channels, reduced bupivacaine-induced cell injury. Therefore, T-type calcium channels may be involved in the neuronal injury observed following local anesthetic administration.

We found that NNC 55-0396 dihydrochloride protection against bupivacaine-induced apoptosis was dose-dependent. Although 10 \(\mu\)M NNC 55-0396 dihydrochloride significantly protected SH-SY5Y cells from 1 mM bupivacaine-induced cell death, the effects of 50 \(\mu\)M NNC 55-0396 dihydrochloride were notably enhanced. However, there was no significant difference between 50 \(\mu\)M and 100 \(\mu\)M NNC 55-0396 dihydrochloride pretreatment, demonstrating that the protection of NNC 55-0396 dihydrochloride exhibited a ceiling effect.

One limitation of this study was that NNC 55-0396 dihydrochloride is not subtype specific, and may have acted on Cav3.1, Cav3.2 and Cav3.3, which are all expressed in SH-SY5Y cells [26]. To investigate the subtypes of T-type calcium channels involved in bupivacaine toxicity, we would like to have employed Cav3.1, Cav3.2 or Cav3.3 specific antagonists. However, to our knowledge, there are currently no drugs available that specifically block Cav3.1, Cav3.2 or Cav3.3. Therefore, genetic engineering to silence subtype gene expression may be necessary to understand the role of specific subtypes in local anesthetic toxicity.

In summary, we found that treatment of SH-SY5Y cells with 1 mM bupivacaine for 24 h resulted in apoptosis, activation of caspase-3 and release of LDH. Interestingly, inhibition of T-type calcium channels with NNC 55-0396 dihydrochloride reduced bupivacaine-induced cell death, suggesting a novel role for these calcium channels in local anesthetic toxicity.
T Type Calcium Channel and Local Anesthetics

Author Contributions
Conceived and designed the experiments: XW. Performed the experiments: SX HL QZ. Analyzed the data: HL HW. Contributed reagents/materials/analysis tools: CY. Wrote the paper: XW.

References

1. Black MJ, Ruscher AE, Lederman J, Chen H (2007) Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: what are the advantages? Ann Surg Oncol 14: 744–749.

2. Franz R, Hartman J, Wright M (2011) Comparison of anesthetic technique on outcomes of endovascular repair of abdominal aortic aneurysms: a five-year review of monitored anesthesia care with local anesthesia vs. general or regional anesthesia. J Cardiovasc Surg (Torino) 52: 567–577.

3. Pollock JE. (2003) Neurotoxicity of intrathecal local anesthetics and transient neurological symptoms. Best Pract Res Clin Anaesthesiol 17: 471–484.

4. Freie H, Van Aken HK (2011) Risks and benefits of thoracic epidural anesthesia. Br J Anaesth 107: 659–668.

5. Capdélila X, Pirat P, Benguier S, Gaertner E, Singelyn F, et al. (2005) Continuous peripheral nerve blocks in hospital wards after orthopedic surgery: a multicenter prospective analysis of the quality of postoperative analgesia and complications in 1,416 patients. Anesthesiology 103: 1035–1045.

6. Kato J, Konishi J, Yoshida H, Furuya T, Kashiwai A, et al. (2011) Cauda equina syndrome following combined spinal and epidural anesthesia: a case report. Can J Anaesth 58: 638–641.

7. Kubota F, Gupta A, Otsurano A, Axelsson K, Bengtsson M (1997) Two cases of cauda equina syndrome following spinal-epidural anesthesia. Reg Anesth 22: 447–450.

8. LiuYC, Wu RS, Wong CS (2003) Unexpected complication of attempted epidural anesthesia: cauda equina syndrome. Anesth Intensive Care 31: 461–464.

9. Friederich P, Schmitz TP (2002) Lidocaine-induced cell death in a human model of neuronal apoptosis. Eur J Anaesthesiol 19: 564–570.

10. Li J, Xu SY, Zhang QQ, Lei HY (2011) Bupivacaine induces reactive oxygen species production via activation of the AMP-activated protein kinase-dependent pathway. Pharmacology 87: 121–129.

11. Perez-Castro R, Patel S, Garavito-Aguilar ZV, Rosenberg A, Recio-Pinto E, et al. (2009) Cytotoxicity of local anesthetics in human neuronal cells. Anesth Analg 108: 997–1007.

12. Johnson ME, Saenz JA, DaSilva AD, Uhl CB, Gores GJ (2002) Effects of local anesthetic on neuronal cytoplasmic calcium and plasma membrane lysis (necrosis) in a cell culture model. Anesthesiology 97: 1466–1476.

13. Ozcan M, Ayar A, Akin E, Ozcan S, Kutlu S (2010) Effects of levobupivacaine and bupivacaine on intracellular calcium signaling in cultured rat dorsal root ganglion neurons. Recept Signal Transduct Res 30: 113–120.

14. Dajas-Bailador FA, Mogg AJ, Wonnacott S (2002) Intracellular Ca2+ signals evoked by stimulation of nicotinic acetylcholine receptors in SH-SY5Y cells: contribution of voltage-operated Ca2+ channels and Ca2+ stores. J Neurochem 81: 606–614.

15. Mackrell JJ, Challis RA, O’connell DA, Lai FA, Nahorski SR (1997) Differential expression and regulation of ryanodine receptor and myo-inositol 1,4,5-

16. Fuchs A, Rigaudo M, Sarantopoulos CD, Filip P, Hogan QH (2007) Contribution of calcium channel subtypes to the intracellular calcium signal in sensory neurons: the effect of injury. Anesthesiology 107: 117–127.

17. Perez-Reyes E (2006) Molecular characterization of T-type calcium channels. Cell Calcium 40: 89–96.

18. Jagodic MM, Pathiratna S, Jokovic PM, Lee W, Nelson MT, et al. (2008) Upregulation of T-type calcium current in small rat sensory neurons after chronic constriction injury of the sciatic nerve. J Neurophysiol 99: 3151–3156.

19. Wen XJ, Xu SY, Chen ZX, Yang CX, Liang H, et al. (2010) The roles of T-type calcium channel in the development of neuropathic pain following chronic compression of rat dorsal root ganglia. Pharmacology 85: 290–300.

20. Cuener L, Canepari M, Adelman JP, Luthi A (2009) Ca(2+)-signaling by T-type Ca(2+)-channels in neurons. Pflugers Arch Eur J Physiol 457: 1161–1172.

21. Szwadzki A, Liu Q, Wang Y, Melander A, Jeppsson B, et al. (2008) Verapamil inhibits L-type calcium channel mediated apoptosis in human colon cancer cells. Dis Colon Rectum 51: 1696–1702.

22. Leski ML, Valentine SL, Coyle JT (1999) L-type voltage-gated calcium channels modulate kainic acid neurotoxicity in cerebellar granule cells. Brain Res 828: 27–40.

23. Yagami T, Ueda K, Sakaida T, Iho N, Sakaguchi G, et al. (2004) Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol 67: 1153–1165.

24. Li M, Hansen JB, Huang LP, Keyser BM, Taylor JT (2005) Towards selective antagonists of T-type calcium channels: design, characterization and potential applications of NNC 55–0396. Cardiovascular Drug Reviews 23: 173–196.

25. Lu J, Xu SY, Zhang QQ, Xu R, Lei HY (2011) Bupivacaine induces apoptosis via mitochondria and p38 MAPK dependent pathways. Eur J Pharmacol 637: 51–56.

26. Kim JA, Li L, Zuo Z (2009) Isoflurane induces a postconditioning effect on bovine pulmonary arterial endothelial cells exposed to oxygen-glucose deprivation. Eur J Pharmacol 615: 144–149.

27. Yang S, Abrahams MS, Hurn PD, Grafe MR, Kirsch JR (2011) Local anesthetic Schwann cell toxicity is time and concentration dependent. Reg Anesth Pain Med 36: 444–451.

28. Wen XJ, Li JJ, Chen ZX, Fang ZY, Yang CX, et al. (2006) Intrathecal administration of Cav.3.2 and Cav.3.3 antisense oligonucleotide reverses tactile allodynia and thermal hyperalgesia in rats following chronic compression of dorsal root of ganglion. Acta Pharmacol Sin 27: 1547–1552.

29. Wen XJ, Xu SY, Wang LL, Liang H, Yang CY, et al. (2011) T-type calcium channel expression in cultured human neuroblastoma cells. Neuronal Regen Res 6: 2410–2413.